RPCA
WVE icon

Running Point Capital Advisors’s Wave Life Sciences WVE Stock Holding History

Running Point Capital Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$70K – 207
2022
Q4 		$70K Hold
10,000
– – 0.04% 155
2022
Q3 		$36K Hold
10,000
– – 0.02% 163
2022
Q2 		$33K Hold
10,000
– – 0.02% 168
2022
Q1 		$20K Buy
+10,000
New +$24.5K 0.01% 188

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Running Point Capital Advisors's WVE Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Wave Life Sciences (WVE) in Q1 2023, closing a stake of 10,000 shares — an estimated $70K sold.

Running Point Capital Advisors first reported a position in WVE in Q1 2022 and held it in 4 quarters. The position peaked at $70K in Q4 2022. 72 funds tracked by Wall St. Rank hold WVE as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Wave Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Wave Life Sciences shares in Q1 2023, an estimated $70K.
  • Running Point Capital Advisors first reported a position in Wave Life Sciences in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Wave Life Sciences position peaked at $70K in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.